Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O14733
UPID:
MP2K7_HUMAN
Alternative names:
JNK-activating kinase 2; MAPK/ERK kinase 7; Stress-activated protein kinase kinase 4; c-Jun N-terminal kinase kinase 2
Alternative UPACC:
O14733; B2R9S5; D6W659; O14648; O14816; O60452; O60453; Q1PG43; Q8IY10
Background:
Dual specificity mitogen-activated protein kinase kinase 7 (MAP2K7), also known as JNK-activating kinase 2 and MAPK/ERK kinase 7, plays a pivotal role in the MAP kinase signal transduction pathway. It is a key component of the SAP/JNK signaling pathway, activated by pro-inflammatory cytokines, leading to apoptosis through mitochondrial death signaling pathways, including cytochrome c release.
Therapeutic significance:
Understanding the role of Dual specificity mitogen-activated protein kinase kinase 7 could open doors to potential therapeutic strategies.